Clinical Trial Update: The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients [Phase 4]

View source ↗

Summary

This Phase 4 trial assesses the safety and efficacy of Albis in preventing aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer
• Peptic Ulcer Disease

Drugs mentioned

• Albis

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Patients Taking Low-dose Aspirin | Phase 4 | Status: UNKNOWN